Aceragen, Inc.

NasdaqCM:ACGN Stock Report

Market Cap: US$3.2m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Aceragen Management

Management criteria checks 3/4

Aceragen's CEO is John Taylor, appointed in Sep 2022, he has a tenure of less than a year. His total yearly compensation is $444.06K , comprised of 17.5% salary and 82.5% bonuses, including company stock and options. He directly owns 17.45% of the company’s shares, worth $558.40K. The average tenure of the management team and the board of directors is 4.1 years and 4.3 years respectively.

Key information

John Taylor

Chief executive officer

US$444.1k

Total compensation

CEO salary percentage17.48%
CEO tenureless than a year
CEO ownership17.5%
Management average tenure4.1yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

Seeking Alpha Sep 28

Idera Pharmaceuticals completes acquisition of Aceragen

Idera Pharmaceuticals (NASDAQ:IDRA) has completed the acquisition of privately-held biotechnology company Aceragen in a stock-for-stock transaction. The acquisition, not subject to the approval of Idera stockholders, was unanimously approved by the board of both the companies. The combined cash of the two companies is expected help in funding the advancement of Aceragen's pipeline through 2023. Idera's former CEO, Vincent Milano, has been named board chair. Aceragen's former CEO, John Taylor, succeeds Milano. Additionally, Aceragen's former chief medical officer, Carl Kraus, will serve in that role for Idera. Also, Aceragen's former COO, Daniel Salain, will serve in that role for Idera. And, Andy Jordan, Aceragen's former CFO has been appointed chief strategy officer for Idera. IDRA shares were trading +19.85% post-market. Source: Press Release
Analysis Article Aug 24

We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article May 11

We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article Mar 07

Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article Jan 31

When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?

With the business potentially at an important milestone, we thought we'd take a closer look at Idera Pharmaceuticals...
Analysis Article Dec 27

Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?

If you want to know who really controls Idera Pharmaceuticals, Inc. ( NASDAQ:IDRA ), then you'll have to look at the...
Analysis Article Dec 27

Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

We'd be surprised if Idera Pharmaceuticals, Inc. ( NASDAQ:IDRA ) shareholders haven't noticed that the President...
Analysis Article Nov 25

We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, Idera Pharmaceuticals...

CEO Compensation Analysis

How has John Taylor's remuneration changed compared to Aceragen's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2023n/an/a

-US$41m

Dec 31 2022US$444kUS$78k

-US$23m

Compensation vs Market: John's total compensation ($USD444.06K) is below average for companies of similar size in the US market ($USD760.57K).

Compensation vs Earnings: Insufficient data to compare John's compensation with company performance.


CEO

John Taylor (52 yo)

less than a year
Tenure
US$444,062
Compensation

Mr. John C. Taylor serves as President, Chief Executive Officer and Director since September 28, 2022 at Aceragen, Inc. He was Chief Executive Officer of Spyryx Biosciences, Inc since December 2013 and ser...


Leadership Team

NamePositionTenureCompensationOwnership
John Taylor
Presidentless than a yearUS$444.06k17.45%
$ 558.4k
Gwen Thomas
Associate Director of Human Resourcesno datano datano data
Christina Amendola
Director of Human Resourcesno datano datano data
Brian Jackey
Senior Vice President of Technical Operationsno datano datano data
Deepa Nagpal
Global Head of Qualityno datano datano data
Shah Rahimian
Medical Director & Global Clinical Lead for Oncologyno datano datano data
Joanna Horobin
Advisor4.1yrsUS$993.93kno data
Louis Arcudi
Adviserno dataUS$986.13kno data
4.1yrs
Average Tenure
62yo
Average Age

Experienced Management: ACGN's management team is considered experienced (4.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
John Taylor
Presidentless than a yearUS$444.06k17.45%
$ 558.4k
Michael Dougherty
Independent Director4.3yrsUS$89.43k0.26%
$ 8.4k
Vincent Milano
Chair of the Board of Directors8.7yrsUS$1.43m0.10%
$ 3.2k
Ronald Wooten
Independent Directorless than a yearUS$11.88kno data
Maxine Gowen
Independent Director7.6yrsUS$66.24k0%
$ 0
Cristina Csimma
Independent Director4.3yrsUS$60.12k0%
$ 0
V. Sutton
Member of Scientific Advisory Boardno datano datano data
Edward Schuchman
Member of Scientific Advisory Boardno datano datano data
Atul Chopra
Member of Scientific Advisor Boardno datano data14.31%
$ 458.0k
4.3yrs
Average Tenure
63.5yo
Average Age

Experienced Board: ACGN's board of directors are considered experienced (4.3 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/08/23 12:47
End of Day Share Price 2023/08/21 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aceragen, Inc. is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael UlzBaird
Michael KingCitizens JMP Securities, LLC
Matthew BannonJ.P. Morgan